These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27166257)

  • 1. Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.
    Mouti MA; Dee C; Coupland SE; Hurlstone AF
    Oncotarget; 2016 Jun; 7(26):39654-39670. PubMed ID: 27166257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
    Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
    Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
    Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
    Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MITF deficiency accelerates GNAQ-driven uveal melanoma.
    Phelps GB; Hagen HR; Amsterdam A; Lees JA
    Proc Natl Acad Sci U S A; 2022 May; 119(19):e2107006119. PubMed ID: 35512098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.
    Perez DE; Henle AM; Amsterdam A; Hagen HR; Lees JA
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):604-613. PubMed ID: 29570931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
    Moore AR; Ran L; Guan Y; Sher JJ; Hitchman TD; Zhang JQ; Hwang C; Walzak EG; Shoushtari AN; Monette S; Murali R; Wiesner T; Griewank KG; Chi P; Chen Y
    Cell Rep; 2018 Feb; 22(9):2455-2468. PubMed ID: 29490280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MITF deficiency and oncogenic GNAQ each promote proliferation programs in zebrafish melanocyte lineage cells.
    Phelps GB; Amsterdam A; Hagen HR; García NZ; Lees JA
    Pigment Cell Melanoma Res; 2022 Sep; 35(5):539-547. PubMed ID: 35869673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uveal melanocytes express high constitutive levels of MMP-8 which can be upregulated by TNF-α via the MAPK pathway.
    Hu DN; Rosen RB; Chan CC; Yang WE; Yang SF
    Exp Eye Res; 2018 Oct; 175():181-191. PubMed ID: 29935949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of uveal melanoma oncogenes.
    Ma J; Weng L; Bastian BC; Chen X
    Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice.
    Huang JL; Urtatiz O; Van Raamsdonk CD
    Cancer Res; 2015 Aug; 75(16):3384-97. PubMed ID: 26113083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic mutations in GNAQ occur early in uveal melanoma.
    Onken MD; Worley LA; Long MD; Duan S; Council ML; Bowcock AM; Harbour JW
    Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5230-4. PubMed ID: 18719078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
    Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
    Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
    Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.